ALLOGENEIC STEM-CELL TRANSPLANTATION FOR ADVANCED MYCOSIS FUNGOIDES/SEZARY SYNDROME
(Abstract release date: 05/21/15)
EHA Library. Atilla E. 06/12/15; 102659; PB1665
Dr. Erden Atilla
Contributions
Contributions
Abstract
Abstract: PB1665
Type: Publication Only
Background
T-cell lymphomas are heterogeneous group of diseases that account for < 10% of non-Hodgkin lymphomas. The prognosis for patients with most forms of T-cell lymphoma is generally poor. Mycosis fungoides (MF) and Sezary Syndrome (SS) are cutaneous T cell lymphomas. Several studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) may improve survival in advanced MF and SS.
Aims
We aim to present the outcome of our patients with MF or SS who underwent HSCT
Methods
We retrospectively evaluated totally 8 patients, 5 advanced stage MF and 3 SS who underwent peripheral HSCT rescue at Ankara University Department of Hematology from Oct 2012 to Oct 2014. Three MF patients had large cell transformation at pre-transplantation period. All of the patients received at least three lines of therapy prior to HSCT (Table). Two out of 8 patients were transplanted from unrelated HLA one antigen or allele mismatch donors whereas other 6 patients had fully matched siblings. All of the patients had refractory disease prior to HSCT, 6 of 8 patients received reduced intensity conditioning regimen (Fludarabine-Cyclophosphamide-TBI +/-ATG) while 2 patients received myeloablative conditioning regimens including Cyclophosphamide plus total body irradiation. Peripheral blood was the stem cell source in all the patients. For graft-versus host disease prophylaxis, patients received cyclosporine plus methotrexate or mycophenolate mofetil except one patient in whom metal-prednisolone was used due to renal toxicity.
Results
The median age of the group was 59 years (range 49-61). The median time from diagnosis to HSCT was 3 years (range 1-11 years). The Sorror HCT-CI scores prior to HSCT were listed as: 2/8 score of 0, 3/8 score of 1, 3/8 score of 2. The patients achieved engraftment at a median of 12 days after HSCT (range 0-22). We evaluated the disease response in only 6 patients because two patients died of the early transplant-related mortality in 16th day of the transplantation due to fungal or Acinetobacter infection. Disease responses after the transplantation could evaluated in only six patients as follows: 2 complete remissions, 2 very good partial remission (VGPR), and 2 minimal responses. We obtained complete remission in one patients with VGPR after developing acute GvHD.
Summary
Our results in a small patient group suggest that allo-HSCT is an effective treatment in the patients with advanced stage refractory MF/SS.
Session topic: Publication Only
Type: Publication Only
Background
T-cell lymphomas are heterogeneous group of diseases that account for < 10% of non-Hodgkin lymphomas. The prognosis for patients with most forms of T-cell lymphoma is generally poor. Mycosis fungoides (MF) and Sezary Syndrome (SS) are cutaneous T cell lymphomas. Several studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) may improve survival in advanced MF and SS.
Aims
We aim to present the outcome of our patients with MF or SS who underwent HSCT
Methods
We retrospectively evaluated totally 8 patients, 5 advanced stage MF and 3 SS who underwent peripheral HSCT rescue at Ankara University Department of Hematology from Oct 2012 to Oct 2014. Three MF patients had large cell transformation at pre-transplantation period. All of the patients received at least three lines of therapy prior to HSCT (Table). Two out of 8 patients were transplanted from unrelated HLA one antigen or allele mismatch donors whereas other 6 patients had fully matched siblings. All of the patients had refractory disease prior to HSCT, 6 of 8 patients received reduced intensity conditioning regimen (Fludarabine-Cyclophosphamide-TBI +/-ATG) while 2 patients received myeloablative conditioning regimens including Cyclophosphamide plus total body irradiation. Peripheral blood was the stem cell source in all the patients. For graft-versus host disease prophylaxis, patients received cyclosporine plus methotrexate or mycophenolate mofetil except one patient in whom metal-prednisolone was used due to renal toxicity.
Results
The median age of the group was 59 years (range 49-61). The median time from diagnosis to HSCT was 3 years (range 1-11 years). The Sorror HCT-CI scores prior to HSCT were listed as: 2/8 score of 0, 3/8 score of 1, 3/8 score of 2. The patients achieved engraftment at a median of 12 days after HSCT (range 0-22). We evaluated the disease response in only 6 patients because two patients died of the early transplant-related mortality in 16th day of the transplantation due to fungal or Acinetobacter infection. Disease responses after the transplantation could evaluated in only six patients as follows: 2 complete remissions, 2 very good partial remission (VGPR), and 2 minimal responses. We obtained complete remission in one patients with VGPR after developing acute GvHD.
Acute GvHD developed in 57.1 % of the patients (4/7). Chronic GvHD was detected in 3 out of 5 patients surviving longer than 100 days after the transplantation. Early transplant-related mortality was seen in 25%. Our follow-up was changing between 16 days and 769 days. The possibility of two-year progression free and overall survival was 37.5%±1.7% and 62.5%±1.7%, respectively.
Summary
Our results in a small patient group suggest that allo-HSCT is an effective treatment in the patients with advanced stage refractory MF/SS.
Session topic: Publication Only
Abstract: PB1665
Type: Publication Only
Background
T-cell lymphomas are heterogeneous group of diseases that account for < 10% of non-Hodgkin lymphomas. The prognosis for patients with most forms of T-cell lymphoma is generally poor. Mycosis fungoides (MF) and Sezary Syndrome (SS) are cutaneous T cell lymphomas. Several studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) may improve survival in advanced MF and SS.
Aims
We aim to present the outcome of our patients with MF or SS who underwent HSCT
Methods
We retrospectively evaluated totally 8 patients, 5 advanced stage MF and 3 SS who underwent peripheral HSCT rescue at Ankara University Department of Hematology from Oct 2012 to Oct 2014. Three MF patients had large cell transformation at pre-transplantation period. All of the patients received at least three lines of therapy prior to HSCT (Table). Two out of 8 patients were transplanted from unrelated HLA one antigen or allele mismatch donors whereas other 6 patients had fully matched siblings. All of the patients had refractory disease prior to HSCT, 6 of 8 patients received reduced intensity conditioning regimen (Fludarabine-Cyclophosphamide-TBI +/-ATG) while 2 patients received myeloablative conditioning regimens including Cyclophosphamide plus total body irradiation. Peripheral blood was the stem cell source in all the patients. For graft-versus host disease prophylaxis, patients received cyclosporine plus methotrexate or mycophenolate mofetil except one patient in whom metal-prednisolone was used due to renal toxicity.
Results
The median age of the group was 59 years (range 49-61). The median time from diagnosis to HSCT was 3 years (range 1-11 years). The Sorror HCT-CI scores prior to HSCT were listed as: 2/8 score of 0, 3/8 score of 1, 3/8 score of 2. The patients achieved engraftment at a median of 12 days after HSCT (range 0-22). We evaluated the disease response in only 6 patients because two patients died of the early transplant-related mortality in 16th day of the transplantation due to fungal or Acinetobacter infection. Disease responses after the transplantation could evaluated in only six patients as follows: 2 complete remissions, 2 very good partial remission (VGPR), and 2 minimal responses. We obtained complete remission in one patients with VGPR after developing acute GvHD.
Summary
Our results in a small patient group suggest that allo-HSCT is an effective treatment in the patients with advanced stage refractory MF/SS.
Session topic: Publication Only
Type: Publication Only
Background
T-cell lymphomas are heterogeneous group of diseases that account for < 10% of non-Hodgkin lymphomas. The prognosis for patients with most forms of T-cell lymphoma is generally poor. Mycosis fungoides (MF) and Sezary Syndrome (SS) are cutaneous T cell lymphomas. Several studies have suggested that allogeneic hematopoietic stem cell transplantation (HSCT) may improve survival in advanced MF and SS.
Aims
We aim to present the outcome of our patients with MF or SS who underwent HSCT
Methods
We retrospectively evaluated totally 8 patients, 5 advanced stage MF and 3 SS who underwent peripheral HSCT rescue at Ankara University Department of Hematology from Oct 2012 to Oct 2014. Three MF patients had large cell transformation at pre-transplantation period. All of the patients received at least three lines of therapy prior to HSCT (Table). Two out of 8 patients were transplanted from unrelated HLA one antigen or allele mismatch donors whereas other 6 patients had fully matched siblings. All of the patients had refractory disease prior to HSCT, 6 of 8 patients received reduced intensity conditioning regimen (Fludarabine-Cyclophosphamide-TBI +/-ATG) while 2 patients received myeloablative conditioning regimens including Cyclophosphamide plus total body irradiation. Peripheral blood was the stem cell source in all the patients. For graft-versus host disease prophylaxis, patients received cyclosporine plus methotrexate or mycophenolate mofetil except one patient in whom metal-prednisolone was used due to renal toxicity.
Results
The median age of the group was 59 years (range 49-61). The median time from diagnosis to HSCT was 3 years (range 1-11 years). The Sorror HCT-CI scores prior to HSCT were listed as: 2/8 score of 0, 3/8 score of 1, 3/8 score of 2. The patients achieved engraftment at a median of 12 days after HSCT (range 0-22). We evaluated the disease response in only 6 patients because two patients died of the early transplant-related mortality in 16th day of the transplantation due to fungal or Acinetobacter infection. Disease responses after the transplantation could evaluated in only six patients as follows: 2 complete remissions, 2 very good partial remission (VGPR), and 2 minimal responses. We obtained complete remission in one patients with VGPR after developing acute GvHD.
Acute GvHD developed in 57.1 % of the patients (4/7). Chronic GvHD was detected in 3 out of 5 patients surviving longer than 100 days after the transplantation. Early transplant-related mortality was seen in 25%. Our follow-up was changing between 16 days and 769 days. The possibility of two-year progression free and overall survival was 37.5%±1.7% and 62.5%±1.7%, respectively.
Summary
Our results in a small patient group suggest that allo-HSCT is an effective treatment in the patients with advanced stage refractory MF/SS.
Session topic: Publication Only
{{ help_message }}
{{filter}}